In both xenograft and carcinogen-induced animal models of pancreatic cancer, DMAPT inhibits the activity of NF-κB and shows therapeutic promise in combination with the anti-inflammatory agents sulindac or celecoxib in vivo[15,16]. The gene discussed is NFKB1; the disease is pancreatic neoplasm.